Meridian Bioscience, Inc. (VIVO) Reaches $13.77 After 4.00% Down Move, Central Europe Russia & Turkey Fund Has 0.78 Sentiment

June 6, 2017 - By Adrian Mccoy

The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) is a huge mover today! About 90,548 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has declined 26.84% since June 6, 2016 and is downtrending. It has underperformed by 43.54% the S&P500.The move comes after 6 months negative chart setup for the $585.50M company. It was reported on Jun, 6 by Barchart.com. We have $13.22 PT which if reached, will make NASDAQ:VIVO worth $23.42M less.

The Central Europe, Russia and Turkey Fund, Inc. is a non-diversified, closed-end management investment company. The company has market cap of $161.73 million. The Fund seeks long-term capital appreciation through investment in equity or equity-linked securities of issuers domiciled in Central Europe, Russia and Turkey. It currently has negative earnings. Under normal circumstances, the Fund will invest at least 80% of its net assets (plus borrowings used for investment purposes) in securities of issuers domiciled in Central Europe, Russia and Turkey.

Since January 26, 2017, it had 2 buys, and 0 selling transactions for $101,156 activity. 4,000 shares were bought by LUEKE MELISSA, worth $50,356 on Thursday, February 2. BALDINI LAWRENCE bought 4,000 shares worth $50,800.

Investors sentiment increased to 1.27 in 2016 Q4. Its up 0.05, from 1.22 in 2016Q3. It is positive, as 14 investors sold Meridian Bioscience, Inc. shares while 48 reduced holdings. 24 funds opened positions while 55 raised stakes. 35.77 million shares or 1.94% less from 36.48 million shares in 2016Q3 were reported. Sunbelt reported 1,022 shares. Parkside Comml Bank & invested 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). 21,515 are owned by Tudor Investment Et Al. Pnc Finance Ser Gp Inc accumulated 97,984 shares. Hancock Holdg holds 39,699 shares or 0.03% of its portfolio. Robeco Institutional Asset Mngmt Bv stated it has 0.01% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Fifth Third National Bank & Trust owns 0.05% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 304,313 shares. Connors Investor has invested 0.43% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). New York-based Morgan Stanley has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Invesco owns 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 486,490 shares. State Of Tennessee Treasury Department holds 0% or 33,284 shares. Nationwide Fund Advsrs invested in 0.02% or 210,644 shares. Blackrock Inv Mngmt Ltd Llc holds 0% or 217,950 shares in its portfolio. 1.00 million were accumulated by Price T Rowe Assoc Inc Md. Panagora Asset Mgmt owns 1,724 shares for 0% of their portfolio.

Among 3 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Meridian Bioscience had 6 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Hold” rating given on Thursday, September 10 by Canaccord Genuity. On Monday, March 21 the stock rating was downgraded by Hilliard Lyons to “Neutral”. Hilliard Lyons upgraded Meridian Bioscience, Inc. (NASDAQ:VIVO) on Monday, March 28 to “Buy” rating.

Analysts await Meridian Bioscience, Inc. (NASDAQ:VIVO) to report earnings on July, 27. They expect $0.16 EPS, down 23.81% or $0.05 from last year’s $0.21 per share. VIVO’s profit will be $6.80 million for 21.52 P/E if the $0.16 EPS becomes a reality. After $0.22 actual EPS reported by Meridian Bioscience, Inc. for the previous quarter, Wall Street now forecasts -27.27% negative EPS growth.

Meridian Bioscience, Inc. is a life science firm engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction /quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. The company has market cap of $585.50 million. The Company’s divisions include Diagnostics and Life Science. It has a 19.62 P/E ratio. The Diagnostics segment includes manufacturing activities in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA.

About 440 shares traded. Central Europe Russia and Turkey Fnd Inc (CEE) has risen 21.02% since June 6, 2016 and is uptrending. It has outperformed by 4.32% the S&P500.

City Of London Investment Management Co Ltd holds 2.57% of its portfolio in Central Europe Russia and Turkey Fnd Inc for 1.56 million shares. 1607 Capital Partners Llc owns 289,826 shares or 0.4% of their US portfolio. Moreover, Meridian Investment Counsel Inc. has 0.36% invested in the company for 26,560 shares. The Texas-based Doliver Capital Advisors Inc. has invested 0.3% in the stock. Montgomery Investment Management Inc, a Maryland-based fund reported 20,920 shares.